Vivo Capital bags $635M for its new biotech public company fund
Vivo Capital has raised a whopping $635 million for a new biotech public company fund — pretty much perfect timing for an investment group with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
